Oxidative stress reduction related to the efficacy of n-3 polyunsaturated fatty acids in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized trial

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 121, Issue , 2017, Pages 7-13

  Pawelczyk T ^a   Grancow Grabka, M ^b   Trafalska, E ^a   Szemraj, J ^a   Pawelczyk A ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Maria Konopnicka Paediatric Centre   (Poland)

Author keywords

8 epi isoprostane F2 alpha; Docosahexaenoic acid; Eicosapentaenoic acid; Randomized controlled trial; Schizophrenia first episode; Total antioxidant capacity

Indexed keywords

8 EPI ISOPROSTANE F2ALPHA; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; ISOPROSTANE DERIVATIVE; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; PLACEBO; UNCLASSIFIED DRUG; ANTIOXIDANT; ISOPROSTANE F2ALPHA III;

ADD ON THERAPY; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CALGARY DEPRESSION SCALE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; FEMALE; FIRST EPISODE SCHIZOPHRENIA; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SYMPTOM ASSESSMENT; TOTAL ANTIOXIDANT CAPACITY; ADOLESCENT; BLOOD; CONTROLLED STUDY; GENETICS; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIOXIDANTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; ISOPROSTANES; MALE; OXIDATIVE STRESS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 85020022810     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2017.05.004     Document Type: Article

References (51)

1. Bitanihirwe, B.K.Y., Woo, T.-U.W., Oxidative stress in schizophrenia: an integrated approach. Neurosci. Biobehav. Rev. 35 (2011), 878–893.
2. Bansal, M., Kaushal, N., Oxidative Stress Mechanisms and their Modulation. 2014, Springer, New Delhi.
3. Snow, P.J., Free Radicals in the Brain: Aging, Neurological and Mental Disorders. 2012, Springer.
4. Wood, S.J., Yucel, M., Pantelis, C., Berk, M., Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann. Acad. Med Singap., 38, 2009, 396 (396).
5. Yao, J.K., Keshavan, M.S., Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid. Redox Signal 15 (2011), 2011–2035.
6. Emiliani, F.E., Sedlak, T.W., Sawa, A., Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr. Opin. Psychiatry 27 (2014), 185–190.
7. Koga, M., Serritella, A.V., Sawa, A., Sedlak, T.W., Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophr. Res. 176 (2016), 52–71.
8. Flatow, J., Buckley, P., Miller, B.J., Meta-analysis of oxidative stress in schizophrenia. Biol. Psychiatry 74 (2013), 400–409.
9. Greco, A., Minghetti, L., Isoprostanes as biomarkers and mediators of oxidative injury in infant and adult central nervous system diseases. Curr. Neurovascular Res. 1 (2004), 341–354.
10. Zhang, Z.-J., Systematic review on the association between F2-isoprostanes and cardiovascular disease. Ann. Clin. Biochem. 50 (2013), 108–114.
11. Miller, E., Morel, A., Saso, L., Saluk, J., Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases. Oxid. Med. Cell. Longev., 2014, 2014, 572491.
12. Sarandol, A., Kirli, S., Akkaya, C., Altin, A., Demirci, M., Sarandol, E., Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Progress. neuro-Psychopharmacol. Biol. Psychiatry 31 (2007), 1164–1169.
13. Dietrich-Muszalska, A., Olas, B., Isoprostenes as indicators of oxidative stress in schizophrenia. World J. Biol. Psychiatry.: Off. J. World Fed. Soc. Biol. Psychiatry. 10 (2009), 27–33.
14. Fusar-Poli, P., Berger, G., Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J. Clin. Psychopharmacol. 32 (2012), 179–185.
15. Pawelczyk, T., Grancow, M., Kotlicka-Antczak, M., Trafalska, E., Gebski, P., Szemraj, J., Zurner, N., Pawelczyk, A., Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods. BMC Psychiatry, 15, 2015, 97.
16. Pawełczyk, T., Grancow-Grabka, M., Kotlicka-Antczak, M., Trafalska, E., Pawełczyk, A., A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J. Psychiatr. Res. 73 (2016), 34–44.
17. Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., Dunbar, G.C., The mini-International neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59:Suppl 20 (1998), S22–S33 (quiz 34-57).
18. M. Jarema, Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych, Via Medica, Gdańsk, 2011.
19. Kay, S.R., Fiszbein, A., Opler, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987), 261–276.
20. W. Guy, The Clinical Global Impression Scale, in: ECDEU Assessment Manual for Psychopharmacology-Revised, 1976, pp. 218–222.
21. Jones, S.H., Thornicroft, G., Coffey, M., Dunn, G., A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br. J. Psychiatry.: J. Ment. Sci. 166 (1995), 654–659.
22. Addington, D., Addington, J., Maticka-Tyndale, E., Joyce, J., Reliability and validity of a depression rating scale for schizophrenics. Schizophr. Res. 6 (1992), 201–208.
23. Friedman, L.M., Furberg, C., DeMets, D.L., Fundamentals of Clinical Trials. 4th ed, 2010, Springer, New York.
24. Dehghan, M., Ilow, R., Zatonska, K., Szuba, A., Zhang, X., Mente, A., Regulska-Ilow, B., Development, reproducibility and validity of the food frequency questionnaire in the Poland arm of the Prospective Urban and Rural Epidemiological (PURE) study. J. Human. Nutr. Diet.: Off. J. Br. Diet. Assoc. 25 (2012), 225–232.
25. J. Cohen, Statistical Power Analysis for the Behavioral Sciences, 2nd ed. ed., L. Erlbaum Associates, Hillsdale N.J., 1988.
26. Emiliani, F.E., Sedlak, T.W., Sawa, A., Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr. Opin. Psychiatry 27 (2014), 185–190.
27. Khan, M.M., Evans, D.R., Gunna, V., Scheffer, R.E., Parikh, V.V., Mahadik, S.P., Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 58 (2002), 1–10.
28. Hoen, W.P., Lijmer, J.G., Duran, M., Wanders, R.J.A., van Beveren, N.J.M., Haan, L., Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res. 207 (2013), 1–12.
29. Rice, S.M., Schafer, M.R., Klier, C., Mossaheb, N., Vijayakumar, N., Amminger, G.P., Erythrocyte polyunsaturated fatty acid levels in young people at ultra-high risk for psychotic disorder and healthy adolescent controls. Psychiatry Res. 228 (2015), 174–176.
30. Sivrioglu, E.Y., Kirli, S., Sipahioglu, D., Gursoy, B., Sarandol, E., The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Progress. Neuro-Psychopharmacol. Biol. Psychiatry 31 (2007), 1493–1499.
31. Smesny, S., Milleit, B., Schaefer, M.R., Hipler, U.-C., Milleit, C., Wiegand, C., Hesse, J., Klier, C.M., Holub, M., Holzer, I., Berk, M., McGorry, P.D., Sauer, H., Paul Amminger, G., Effects of omega-3 PUFA on the vitamin E and glutathione antioxidant defense system in individuals at ultra-high risk of psychosis. Prostaglandins Leukot. Essent. Fat. Acids, 2015.
32. Amminger, G.P., Schafer, M.R., Papageorgiou, K., Klier, C.M., Cotton, S.M., Harrigan, S.M., Mackinnon, A., McGorry, P.D., Berger, G.E., Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. General. Psychiatry 67 (2010), 146–154.
33. Kiecolt-Glaser, J.K., Belury, M.A., Andridge, R., Malarkey, W.B., Hwang, B.S., Glaser, R., Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain Behav. Immun. 26 (2012), 988–995.
34. Kiecolt-Glaser, J.K., Epel, E.S., Belury, M.A., Andridge, R., Lin, J., Glaser, R., Malarkey, W.B., Hwang, B.S., Blackburn, E., Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: a randomized controlled trial. Brain Behav. Immun. 28 (2013), 16–24.
35. Balcerczyk, A., Gajewska, A., Macierzynska-Piotrowska, E., Pawelczyk, T., Bartosz, G., Szemraj, J., Enhanced Antioxidant Capacity and Anti-ageing Biomarkers After Diet Micronutrient Supplementation, Molecules, 19, 2014, Basel, Switzerland, 14794–14808.
36. Bradbury, J., Docosahexaenoic acid (DHA): an ancient nutrient for the modern human brain. Nutrients 3 (2011), 529–554.
37. Calder, P.C., Mechanisms of action of (n-3) fatty acids. J. Nutr. 142 (2012), 592S–599S.
38. Kirkpatrick, B., Miller, B.J., Inflammation and schizophrenia. Schizophr. Bull. 39 (2013), 1174–1179.
39. Garcia-Bueno, B., Bioque, M., Mac-Dowell, K.S., Barcones, M.F., Martinez-Cengotitabengoa, M., Pina-Camacho, L., Rodriguez-Jimenez, R., Saiz, P.A., Castro, C., Lafuente, A., Santabarbara, J., Gonzalez-Pinto, A., Parellada, M., Rubio, G., Garcia-Portilla, M.P., Mico, J.A., Bernardo, M., Leza, J.C., Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr. Bull. 40 (2014), 376–387.
40. Hammamieh, R., Chakraborty, N., Gautam, A., Miller, S.-A., Muhie, S., Meyerhoff, J., Jett, M., Transcriptomic analysis of the effects of a fish oil enriched diet on murine brains. PLoS One, 9, 2014, e90425.
41. Calder, P.C., n-3 fatty acids, inflammation and immunity: new mechanisms to explain old actions. Proc. Nutr. Soc. 72 (2013), 326–336.
42. Keleshian, V.L., Kellom, M., Kim, H.-W., Taha, A.Y., Cheon, Y., Igarashi, M., Rapoport, S.I., Rao, J.S., Neuropathological responses to chronic NMDA in rats are worsened by dietary n-3 PUFA deprivation but are not ameliorated by fish oil supplementation. PLoS One, 9, 2014, e95318.
43. Patten, A.R., Sickmann, H.M., Dyer, R.A., Innis, S.M., Christie, B.R., Omega-3 fatty acids can reverse the long-term deficits in hippocampal synaptic plasticity caused by prenatal ethanol exposure. Neurosci. Lett. 551 (2013), 7–11.
44. Berger, G.E., Wood, S.J., Wellard, R.M., Proffitt, T.M., McConchie, M., Amminger, G.P., Jackson, G.D., Velakoulis, D., Pantelis, C., McGorry, P.D., Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Biol. Psychiatry 33 (2008), 2467–2473.
45. Berger, G.E., Proffitt, T.-M., McConchie, M., Yuen, H., Wood, S.J., Amminger, G.P., Brewer, W., McGorry, P.D., Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J. Clin. Psychiatry 68 (2007), 1867–1875.
46. Luchtman, D.W., Song, C., Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. Neuropharmacology 64 (2013), 550–565.
47. Savinova, O.V., Fillaus, K., Harris, W.S., Shearer, G.C., Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol. Atherosclerosis 240 (2015), 520–525.
48. Takkunen, M.J., Schwab, U.S., de Mello, V.D.F., Eriksson, J.G., Lindstrom, J., Tuomilehto, J., Uusitupa, M.I.J., Longitudinal associations of serum fatty acid composition with type 2 diabetes risk and markers of insulin secretion and sensitivity in the Finnish Diabetes Prevention Study. Eur. J. Nutr., 2015.
49. T.A. Rix, A.M. Joensen, S. Riahi, S. Lundbye-Christensen, A. Tjonneland, E.B. Schmidt, K. Overvad, A U-shaped association between consumption of marine n-3 fatty acids and development of atrial fibrillation/atrial flutter-a Danish cohort study, Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology, 16, 2014, pp. 1554–1561.
50. Nestel, P., Clifton, P., Colquhoun, D., Noakes, M., Mori, T.A., Sullivan, D., Thomas, B., Indications for Omega-3 long chain polyunsaturated fatty acid in the prevention and treatment of cardiovascular disease. Heart Lung Circ., 2015.
51. Villegas, R., Takata, Y., Murff, H., Blot, W.J., Fish, omega-3 long-chain fatty acids, and all-cause mortality in a low-income US population: results from the Southern Community Cohort Study. Nutr. Metab. Cardiovasc. Dis.: NMCD 25 (2015), 651–658.